Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iso-nexatecan-based GGFG payload
- Development stage
- Preclinical
- Lead developer
- IntoCell
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The iso-nexatecan-based GGFG payload is a proprietary drug-linker technology developed by IntoCell Inc. for use in antibody-drug conjugates (ADCs). This construct consists of iso-nexatecan, a cytotoxic topoisomerase I inhibitor derived from camptothecin analogs, conjugated to a GGFG (glycyl-glycyl-phenylalanyl-glycine) tetrapeptide linker. The GGFG linker is designed to be protease-cleavable, maintaining high stability in systemic circulation but undergoing rapid enzymatic cleavage by lysosomal cathepsins once the ADC is internalized into tumor cells. Upon release, the iso-nexatecan payload inhibits topoisomerase I, leading to DNA strand breaks and subsequent cell death. In October 2025, IntoCell licensed this technology to Piramal Pharma Solutions to expand their bioconjugate development and manufacturing capabilities.
- Other names
- iso-nexatecan GGFG payloadiso-nexatecan-GGFG
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on iso-nexatecan-based GGFG payload.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iso-nexatecan-based GGFG payload.